Sanofi logo

Sanofi

SNY | NASDAQ
Chart Builder DCF Calculator
$48.39
+$0.02 (+0.04%)
At close: Nov 16, 2026, 4:00 PM ET
$48.20
-$0.19 (-0.39%)
After-hours: Nov 16, 2026, 7:56 PM ET
+0.04%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
52.3
Fundamentals Average
Market Sentiment Neutral
Moat Wide
Sector Rank #233/1021 (Top 23%)

Why Price Moved

7 days ago
+2.3%

Shares are trading higher after being featured as ...

Key Statistics

Market Data

Market Cap $116.2B
1D Range
48.33 48.98
52W Range
39.12 51.78

Valuation (TTM)

PE 86.43
PB 1.41
EV/EBITDA 7.88

Valuation (NTM)

Forward PE 10.69
Forward PEG 2.39
Price Target $53.00
Loading financial charts...

Profile

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, E...

Sector Healthcare
Employees 76,493
IPO Date Jul 1, 2002
Fiscal Year January - December

Latest News

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (November 2026)

10 days ago · seekingalpha.com

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (November 2026)
Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272

13 days ago · globenewswire.com

Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272
Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

14 days ago · zacks.com

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues
Sanofi Q3 Earnings Call Highlights

18 days ago · marketbeat.com

Sanofi Q3 Earnings Call Highlights
Dupixent Is Still Booming. Sanofi's CEO Is Already Planning for Life Without It

18 days ago · benzinga.com

Dupixent Is Still Booming. Sanofi's CEO Is Already Planning for Life Without It
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up

18 days ago · 247wallst.com

Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise

18 days ago · zacks.com

Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise
Sanofi CEO Sets Sights on Deals to Drive Turnaround

18 days ago · wsj.com

Sanofi CEO Sets Sights on Deals to Drive Turnaround
Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings

22 days ago · 247wallst.com

Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings
Sanofi: An Alluring And Balanced Mix Of Yield And Growth

22 days ago · seekingalpha.com

Sanofi: An Alluring And Balanced Mix Of Yield And Growth

Earnings

Latest Earnings
Oct 30, 2026
EPS
$2.04
Beat +25.15%
REV
$17.02B
Beat +18.87%
Next Earnings
Feb 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Hold
Price Target
$53.00
Upside
+9.53%
Buy (0)
Hold (7)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.